- Chief, Pediatric Cardiac Critical Care, UH Rainbow Babies and Children's Hospital
- Associate Chief Quality Officer, Patient Safety, UH Rainbow Babies and Children's Hospital
- Professor, CWRU School of Medicine
Ira Cheifetz, MD, is the Division Chief for Cardiac Critical Care and Associate Chief Quality Officer for Patient Safety at University Hospitals Rainbow Babies and Children’s, and the KeyBank-Meyer Family Chair and Professor of Pediatrics at Case Western Reserve University School of Medicine. Dr. Cheifetz is a pediatric cardiac intensivist with focused expertise in congenital and pediatric acquired heart disease, postoperative cardiac care, cardiorespiratory interactions, mechanical ventilation and extracorporeal life support. He is also an active clinical and translational NIH funded researcher who has authored more than 200 peer-reviewed publications and chapters, and presented at numerous national and international scientific symposia.
- Acute Respiratory Distress Syndrome (ARDS)
- Cardiorespiratory Interactions
- Congenital Heart Disease
- Extracorporeal Membrane Oxygenation (ECMO)
- Mechanical Ventilation
- Pediatric Cardiac Critical Care
- Pediatric Critical Care
Research & Publications
Cardiac critical care, congenital heart disease, mechanical ventilation, cadiorespiratory interactions, acute lung injury, extracorporeal life support
Certifications & Memberships
- Pediatric Critical Care Medicine - American Board of Pediatrics
- Pediatrics - American Board of Pediatrics
Fellowship | Pediatric Critical Care Medicine
Pediatric Critical Care Medicine - Duke University Medical Center (1993 - 1996)
Residency | Pediatrics/Chief Resident
Pediatrics/Chief Resident - Duke University Medical Center (1992 - 1993)
Residency | Pediatrics
Pediatrics - Duke University Medical Center (1989 - 1992)
Yale University School Of Medicine (1989)
Rensselaer Polytech Institute (1985)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Ira Cheifetz did not disclose any Outside Relationships with Industry.